70 related articles for article (PubMed ID: 21233691)
1. Developing an assay for ceftazidime: is it worth the effort?
van den Anker J
Ther Drug Monit; 2011 Feb; 33(1):132. PubMed ID: 21233691
[No Abstract] [Full Text] [Related]
2. Prospective determination of serum ceftazidime concentrations in intensive care units.
Aubert G; Carricajo A; Coudrot M; Guyomarc'h S; Auboyer C; Zeni F
Ther Drug Monit; 2010 Aug; 32(4):517-9. PubMed ID: 20571462
[TBL] [Abstract][Full Text] [Related]
3. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
Conil JM; Georges B; Lavit M; Laguerre J; Samii K; Houin G; Saivin S
Br J Clin Pharmacol; 2007 Jul; 64(1):27-35. PubMed ID: 17324245
[TBL] [Abstract][Full Text] [Related]
4. [Interest in therapeutic drug monitoring of the main antibiotics].
Davani S; Muret P; Royer B; Hoen B; Kantelip JP
Ann Biol Clin (Paris); 2002; 60(6):655-61. PubMed ID: 12446229
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ceftazidime after intravenous, intramuscular and subcutaneous administration to dogs.
Monfrinotti A; Ambros L; Prados AP; Kreil V; Rebuelto M
J Vet Pharmacol Ther; 2010 Apr; 33(2):204-7. PubMed ID: 20444047
[No Abstract] [Full Text] [Related]
6. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.
Georges B; Conil JM; Seguin T; Ruiz S; Minville V; Cougot P; Decun JF; Gonzalez H; Houin G; Fourcade O; Saivin S
Antimicrob Agents Chemother; 2009 Oct; 53(10):4483-9. PubMed ID: 19635962
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers.
Adamis G; Papaioannou MG; Giamarellos-Bourboulis EJ; Gargalianos P; Kosmidis J; Giamarellou H
Int J Antimicrob Agents; 2004 Feb; 23(2):144-9. PubMed ID: 15013039
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Mouton JW; Punt N; Vinks AA
Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.
Thurmann-Nielsen E; Walstad RA; Dahl K; Hellum KB
J Chemother; 1989 Jul; 1(4 Suppl):534-5. PubMed ID: 16312519
[No Abstract] [Full Text] [Related]
10. Penetration of ceftazidime into extracellular fluid in patients.
Hoffstedt B; Walder M
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():289-92. PubMed ID: 19803000
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
[TBL] [Abstract][Full Text] [Related]
12. Renal elimination of ceftazidime during pregnancy.
Nathorst-Böös J; Philipson A; Hedman A; Arvisson A
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):163-6. PubMed ID: 7847529
[TBL] [Abstract][Full Text] [Related]
13. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients.
Roberts JA; Webb SA; Lipman J
Int J Antimicrob Agents; 2007 Feb; 29(2):117-28. PubMed ID: 17158033
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
Bassetti M; Righi E; Rosso R; Mannelli S; Di Biagio A; Fasce R; Pallavicini FB; Marchetti F; Viscoli C
Int J Antimicrob Agents; 2006 Dec; 28(6):582-5. PubMed ID: 16979877
[TBL] [Abstract][Full Text] [Related]
15. Drugs in liver disease and during albumin dialysis -MARS.
Majcher-Peszynska J; Peszynski P; Müller SC; Klammt S; Wacke R; Mitzner S; Stange J; Mundkowski R; Hehl EM; Schmidt R; Drewelow B
Z Gastroenterol; 2001 Jun; 39 Suppl 2():33-5. PubMed ID: 16215894
[No Abstract] [Full Text] [Related]
16. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
McKinnon PS; Paladino JA; Schentag JJ
Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic studies of ceftazidime in serum, bone, bile, tissue fluid and peritoneal fluid.
Wittmann DH; Schassan HH; Kohler F; Seibert W
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():293-7. PubMed ID: 19803001
[TBL] [Abstract][Full Text] [Related]
18. Preliminary experience with ceftazidime monotherapy in perinatal infection.
Amato M; Schaad UB
Helv Paediatr Acta; 1987; 42(4):297-303. PubMed ID: 3127359
[TBL] [Abstract][Full Text] [Related]
19. [Use of aminoglycosides in Danish intensive care units].
Thorvaldsen M; Christrup LL; Bonde J
Ugeskr Laeger; 2004 May; 166(23):2246-50. PubMed ID: 15487522
[No Abstract] [Full Text] [Related]
20. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis.
Soontornpas C; Saraya S; Chulasiri M; Chindavijak B; Mootsikapun P
Int J Antimicrob Agents; 2005 Nov; 26(5):403-7. PubMed ID: 16216470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
